Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pentaerythritol Tetranitrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentaerythritol Tetranitrate SCHEMBL37177 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRTDP1 | |
| Pentaerythritol Tetranitrate SCHEMBL5940085 | 0.97 | ALDH1A1 (0.94) | ALDH1A1 | |
| SCHEMBL7888554 | 0.92 | ALDH1A1 (0.84) | ALDH1A1 | |
| Pentaerythritol Tetranitrate SCHEMBL1028496 | 0.92 | ALDH1A1 (0.84) | ALDH1A1 | |
| Pentaerythritol Tetranitrate SCHEMBL15543872 | 0.87 | ALDH1A1 (0.76) | ALDH1A1TSHR | |
| SCHEMBL7891079 | 0.87 | ALDH1A1 (0.76) | ALDH1A1 | |
| Pentaerythritol Tetranitrate SCHEMBL6686407 | 0.85 | ALDH1A1 (0.73) | ALDH1A1TSHR | |
| Pentrinitrol SCHEMBL122322 | 0.84 | ALDH1A1 (0.71) | ALDH1A1TDP1 | |
| SCHEMBL7894787 | 0.84 | ALDH1A1 (0.71) | ALDH1A1 | |
| SCHEMBL8277378 | 0.84 | ALDH1A1 (0.71) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389534-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2022-07-19 | — | — | US | disclosed |
| US-10946197-B2 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2021-03-16 | — | — | US | disclosed |
| US-10702533-B2 | Treatment of conditions through pharmacological modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2020-07-07 | — | — | US | disclosed |
| US-10086071-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170128457-A1 | Treatment of Conditions Through Pharmacological Modulation of the Autonomic Nervous System | PALO ALTO INVESTORS | 2017-05-11 | — | — | US | disclosed |
| US-9585851-B2 | Treatment of conditions through pharmacological modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160367807-A1 | Treatment of Conditions Through Modulation of the Autonomic Nervous System | PALO ALTO INVESTORS | 2016-12-22 | — | — | US | disclosed |
| US-20140086872-A1 | Methods of Treating a Subject for a Condition | PALO ALTO INVESTORS (US) | 2014-03-27 | — | — | US | disclosed |
| US-8569277-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120270876-A1 | Treatment of Conditions Through Pharmacological Modulation of the Autonomic Nervous System | PALO ALTO INVESTORS | 2012-10-25 | — | — | US | disclosed |
| US-7738952-B2 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100119482-A1 | Treatment of Conditions Through Modulation of the Autonomic Nervous System During at Least One Predetermined Menstrual Cycle Phase | PALO ALTO INVESTORS | 2010-05-13 | — | — | US | disclosed |
| US-7363076-B2 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2008-04-22 | — | — | US | disclosed |
| WO-2007075151-A1 | COMPOSITE VASODILATOR BASED ON A NO-GROUP DONATOR AND A PROMOTER | KUTNYAK VICTOR PAVLOVICH (UA) | 2007-07-05 | — | — | WO | disclosed |
| US-20060034847-A1 | Methods of treating a subject for a condition | PALO ALTO INVESTORS | 2006-02-16 | — | — | US | disclosed |
| US-20050256028-A1 | Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase | PALO ALTO INVESTORS | 2005-11-17 | — | — | US | disclosed |
| US-20050240241-A1 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS | 2005-10-27 | — | — | US | disclosed |
| US-20050153885-A1 | administering aldosterone antagonists such as spironolactone and eplerenone, to increasing the parasympathetic and sympathetic activity | PALO ALTO INVESTORS | 2005-07-14 | — | — | US | disclosed |
| US-20050143378-A1 | Treatment of conditions through pharmacological modulation of the autonomic nervous system | PALO ALTO INVESTORS | 2005-06-30 | — | — | US | disclosed |
| US-20050021092-A1 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS | 2005-01-27 | — | — | US | disclosed |